2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

2:30PM-4:00PM: Abstract Number: 906

Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis

3S090 ACR Abstract: Vasculitis–ANCA-Assocd (904–909)

2:30PM-4:00PM: Abstract Number: 911

Demographic and Clinical Characteristics Reflect Differences in Osteoarthritis Phenotypes of the Lumbar Spine: The Johnston County Osteoarthritis Project

3S093 ACR/ARHP Abstract: Epidemiology & Pub Health (910–915)

2:30PM-4:00PM: Abstract Number: 876

Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease

3S084 ACR Abstract: Muscle Biology, Myositis & Myopathies I: Biomarkers (875–879)

2:30PM-4:00PM: Abstract Number: 844

Differential Roles of Tnfα-TNFR1 and Tnfα-TNFR2 in the Differentiation and Function of Induced CD4+Foxp3+ Treg Cells in Autoimmune Diseases

3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

2:30PM-4:00PM: Abstract Number: 908

Early Prediction of Long-Term Evolutionary Profiles of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Based on Baseline and Follow-up Characteristics

3S090 ACR Abstract: Vasculitis–ANCA-Assocd (904–909)

2:30PM-4:00PM: Abstract Number: 886

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis

3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

2:30PM-4:00PM: Abstract Number: 887

Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards

3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

2:30PM-4:00PM: Abstract Number: 888

Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate

3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

2:30PM-4:00PM: Abstract Number: 898

Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial

3S089 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical I: Clinical Trials I (898–903)

2:30PM-4:00PM: Abstract Number: 860

Efficacy of a Web-Based Module to Educate Internal Medicine Housestaff on Gout

3S081 ACR Abstract: Education (857–862)

2:30PM-4:00PM: Abstract Number: 853

Enhanced Type I Interferon Gene Signature in Primary Antiphospholipid Syndrome: Association with Earlier Disease Onset and Preeclampsia

3S079 ACR Abstract: Antiphospholipid Syndrome (851–856)

2:30PM-4:00PM: Abstract Number: 892

Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)

3S088 ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Axial SpA Epidemiology (892–897)

2:30PM-4:00PM: Abstract Number: 871

Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors

3S083 ACR Abstract: Metabolic & Crystal Arthropathies: Comorbidities & Outcomes (869–874)

2:30PM-4:00PM: Abstract Number: 883

Evaluation of Fracture Risk and Osteoporosis in Males with Rheumatoid Arthritis

3S086 ACR Abstract: RA–DX, Manifestations, & Outcomes I: Other Co-Morbidities (880–885)

2:30PM-4:00PM: Abstract Number: 869

Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout

3S083 ACR Abstract: Metabolic & Crystal Arthropathies: Comorbidities & Outcomes (869–874)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].